ACADIA Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 3/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Catherine Owen Adams
İcra Kurulu Başkanı
US$8.3m
Toplam tazminat
| CEO maaş yüzdesi | 11.26% |
| CEO görev süresi | 2yrs |
| CEO sahipliği | n/a |
| Yönetim ortalama görev süresi | 1.9yrs |
| Yönetim Kurulu ortalama görev süresi | 10.7yrs |
Son yönetim güncellemeleri
Recent updates
Seeking Alpha • Aug 24
Acadia Pharmaceuticals: Another Bite At The Alzheimer's Apple
Summary Acadia will announce phase 2 results for remlifanserin for Alzheimer’s psychosis by September or October. I don't expect positive results based on remlifanserin's mechanism of action. ACAD is cushioned by two approved drugs, Daybue and Nuplazid, generating over $300M in Q2 2026 sales and $32M net income. The company’s nearly $5B market cap and ongoing revenue base mitigate downside risk from a potential remlifanserin failure. Remlifanserin may still advance to phase 3 unless phase 2 results are unequivocally negative, but a substantial stock hit remains possible. The use of peroxnitrite scavengers, provides a promising, alternative approach to treating behavioral and psychological problems in Alzheimer's Disease. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Aug 19
ACAD: RADIANT Phase 2 Alzheimer’s Psychosis Data Will Drive Upside Potential
Analysts have increased their average price targets for ACADIA Pharmaceuticals by a few dollars per share, with higher fair value estimates at $47.18 that reflect increased confidence in remlifanserin and Daybue following recent research updates. Analyst Commentary Recent research coverage on ACADIA Pharmaceuticals points to a broadly constructive stance from bullish analysts, with a series of upward price target revisions clustered around key catalysts for Daybue and remlifanserin.Analiz Makalesi • Aug 08
Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) just released its quarterly report and things are looking bullish. It was...
Anlatı Güncellemesi • Aug 05
ACAD: Future Upside Will Hinge On Alzheimer Psychosis Remlifanserin Data
ACADIA Pharmaceuticals' analyst fair value estimate has been adjusted to $33.25 from $31.80 as analysts factor in stronger Daybue traction, higher long term profit margin assumptions, and the upcoming Phase 2 remlifanserin readout as key supports for higher price targets across the Street. Analyst Commentary Recent research on ACADIA Pharmaceuticals points to a generally constructive tone, with many firms lifting price targets and focusing on execution around Daybue, Nuplazid and the upcoming remlifanserin data.
Anlatı Güncellemesi • Jul 22
ACAD: Alzheimer’s Psychosis Data Will Test High-Risk Remlifanserin Story
Analysts have raised their average price targets on ACADIA Pharmaceuticals by a few dollars per share into the mid $30s, citing expectations for stronger Daybue and Nuplazid trends, as well as updated views on pipeline assets such as remlifanserin and trofinetide, following recent positive CHMP opinions and study designs. Analyst Commentary Recent research on ACADIA Pharmaceuticals points to a mix of optimism around product momentum and caution around execution and drug development risk.Anlatı Güncellemesi • Jun 17
ACAD: Buy Upgrade And Guidance Reaffirmation Will Drive Upside From Pullback
ACADIA Pharmaceuticals' analyst price target has been trimmed by $1, as analysts recalibrate their models around slightly different long term growth, profitability, and discount rate assumptions reflected in recent research updates. Analyst Commentary Recent Street research around ACADIA Pharmaceuticals shows a mix of caution and optimism, with the modest price target trim sitting alongside more constructive views from bullish analysts who see room for the stock to recover from recent weakness.Anlatı Güncellemesi • Jun 02
ACAD: Rett And Alzheimer’s Psychosis Milestones Will Shape Balanced Risk Reward
Analysts have nudged their price expectations for ACADIA Pharmaceuticals higher, with the updated fair value estimate moving from about $19.64 to $19.75 per share as they refine assumptions around growth, margins, and future P/E multiples following recent target changes and rating updates on the stock. Analyst Commentary Recent Street research on ACADIA Pharmaceuticals reflects a mix of optimism and caution, with some firms lifting price targets and others trimming expectations or flagging risks.Anlatı Güncellemesi • May 09
ACAD: Remlifanserin Alzheimer’s Psychosis Readout Will Drive Upside From Undervalued Levels
Analysts recently adjusted their fair value estimate for ACADIA Pharmaceuticals slightly lower to $43.55 from $43.97, reflecting updated assumptions for revenue growth, profitability, and future P/E. This revision also incorporates mixed but generally constructive Street price target updates in the $26 to $37 range, along with several fresh Buy and Outperform ratings.Anlatı Güncellemesi • Apr 23
ACAD: Execution Risk Around Rett Syndrome Setback Will Limit Future Upside
Analysts trimmed the fair value estimate for ACADIA Pharmaceuticals slightly to $19.64 from $19.73, as modestly higher discount rate assumptions offset slightly stronger projected revenue growth and profitability. They maintained a supportive stance following a mix of recent price target increases and reductions across the Street.Anlatı Güncellemesi • Apr 08
ACAD: Future Upside Will Depend On Alzheimer Psychosis Trial Outcomes
The fair value estimate for ACADIA Pharmaceuticals has increased slightly to $31.80, as analysts incorporate updated revenue growth assumptions, mixed adjustments to price targets across firms, and ongoing expectations for contributions from Nuplazid, Daybue, and the broader pipeline. Analyst Commentary Recent research coverage on ACADIA Pharmaceuticals shows a mix of optimism and caution, with several firms revising price targets after earnings updates, guidance, and pipeline commentary.Anlatı Güncellemesi • Mar 24
ACAD: Remlifanserin Alzheimer’s Psychosis Data Will Drive Upside From Undervalued Levels
ACADIA Pharmaceuticals' updated analyst price target moves from $37 to about $44, with analysts pointing to refreshed models that reflect recent guidance, ongoing commercial momentum in Nuplazid and Daybue, and growing attention on the remlifanserin Phase 2 program in Alzheimer's disease psychosis. Analyst Commentary Recent Street research around ACADIA Pharmaceuticals clusters around refreshed models, updated sales assumptions for Nuplazid and Daybue, and rising interest in the remlifanserin program in Alzheimer's disease psychosis.Anlatı Güncellemesi • Mar 10
ACAD: Trofinetide EU Setback And Execution Risks Will Likely Restrain Upside
ACADIA Pharmaceuticals' updated analyst price target reflects a modest reset in fair value to $19.73 from $20.26, as analysts balance recent target revisions across the Street with refreshed assumptions for growth, margins, and future P/E levels. Analyst Commentary Across recent research updates, views on ACADIA are mixed, with several large firms expressing confidence in the commercial trajectory of Nuplazid and Daybue, while others are more measured and focused on execution risks and how much of the current pipeline is already reflected in the share price.Anlatı Güncellemesi • Feb 23
ACAD: Pipeline And Execution Risks Will Likely Cap Upside Despite Renewed Optimism
ACADIA Pharmaceuticals' updated fair value estimate has edged up from $19.65 to $20.26 per share, reflecting analysts' higher price targets tied to confidence in Nuplazid and Daybue, as well as underappreciated upside from the remlifanserin pipeline asset. Analyst Commentary Recent research views on ACADIA are mixed, with some firms pointing to upside tied to Nuplazid, Daybue, and the remlifanserin program, while others are more guarded.Anlatı Güncellemesi • Feb 09
ACAD: Higher P/E Assumptions Will Rely On Successful Rett Syndrome Expansion
Analysts have nudged their fair value estimate for ACADIA Pharmaceuticals higher by about $0.47 per share, reflecting recent price target revisions and updated assumptions around revenue growth, profitability, and future P/E multiples. Analyst Commentary Recent Street research on ACADIA Pharmaceuticals has been active, with multiple firms revising price targets and updating their views on the company.Anlatı Güncellemesi • Jan 25
ACAD: Execution Risk And Sector Capital Pressures Will Likely Constrain Upside
Narrative Update Analysts have lifted their price target on ACADIA Pharmaceuticals to US$40 from US$35, citing updated assumptions around revenue growth, profitability and future P/E expectations, alongside a generally cautious but constructive view on Biotech, with potential M&A activity helping to support the sector. Analyst Commentary While the updated US$40 target signals constructive sentiment on ACADIA Pharmaceuticals, recent commentary still carries a cautious tone around how the story plays out over time.Anlatı Güncellemesi • Jan 11
ACAD: Higher P/E Assumptions Will Support Upside If Pipeline Milestones Deliver
Narrative Update Analysts have lifted their price target on ACADIA Pharmaceuticals to US$40 from US$35, citing a refreshed view on fair value, updated discount rate assumptions, and adjusted expectations for revenue growth, profit margin, and future P/E multiples. Analyst Commentary Recent commentary around ACADIA Pharmaceuticals reflects a mix of optimism on potential value creation and caution around sector level capital trends.Anlatı Güncellemesi • Dec 26
ACAD: Expanded Neuroscience Pipeline Will Drive Upside From Undervalued Levels
Analysts have modestly increased their price target on ACADIA Pharmaceuticals from 35.00 dollars to 37.00 dollars. They cited slightly stronger long term revenue growth, improved profit margin expectations, a marginally lower discount rate, and a higher projected future price to earnings multiple.Anlatı Güncellemesi • Dec 12
ACAD: Upcoming Neuropsychiatric Data Expected To Drive Upside Despite Recent Setback
Analysts have trimmed their price target on ACADIA Pharmaceuticals by $5 to $35 per share. This reflects a modestly higher discount rate and lower long term profit expectations, despite slightly stronger projected revenue growth and reassurance that the ACP-101 failure has only a small impact on overall valuation.Analiz Makalesi • Nov 13
Shareholders Shouldn’t Be Too Comfortable With ACADIA Pharmaceuticals' (NASDAQ:ACAD) Strong Earnings
Even though ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) posted strong earnings recently, the stock hasn't reacted in a...Analiz Makalesi • Nov 09
ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) came out with its quarterly results last week, and we wanted to see how the...Anlatı Güncellemesi • Sep 26
Global Outreach And Pipeline Programs Will Expand CNS Markets
ACADIA Pharmaceuticals’ consensus price target was revised downward to $29.32 as the Phase 3 failure of ACP-101 in Prader-Willi syndrome modestly reduced pipeline value, though the impact is seen as limited given low expectations and resilience in the core business. Analyst Commentary Bearish analysts cite the Phase 3 failure of ACP-101 in Prader-Willi syndrome (PWS), which missed its primary endpoint, leading to lowered price targets based on reduced near-term pipeline value.Anlatı Güncellemesi • Sep 04
Global Outreach And Pipeline Programs Will Expand CNS Markets
Analysts maintained their price target for ACADIA Pharmaceuticals at $29.95 as strong Daybue growth, favorable Nuplazid patent rulings, and strategic R&D focus offset near-term competitive and pipeline uncertainties. Analyst Commentary Bullish analysts are raising price targets citing strong Daybue growth in Q2, but note further acceleration is needed for material upside.Analiz Makalesi • Aug 09
Results: ACADIA Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
NasdaqGS:ACAD 1 Year Share Price vs Fair Value Explore ACADIA Pharmaceuticals's Fair Values from the Community and...Analiz Makalesi • May 30
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Surges 54% Yet Its Low P/S Is No Reason For Excitement
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) shares have had a really impressive month, gaining 54% after a shaky period...Analiz Makalesi • May 09
ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) just released its first-quarter report and things are looking bullish...Analiz Makalesi • Mar 03
ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) last week reported its latest annual results, which makes it a good time...Seeking Alpha • Feb 13
Acadia Pharmaceuticals: Good Progress Means I'm Reversing My 'Sell' Call To 'Buy'
Summary Acadia Pharmaceuticals has shown significant financial improvement, reporting a profit of $82.7m in 2024, compared to a loss of $(107m) in 2023. The company's revenue growth is driven by NUPLAZID and DAYBUE, with 2024 revenue projections of $600m-$610m and $340m-$350m respectively, and overall revenues forecast to exceed $1bn in '25. Acadia's promising pipeline, including ACP-204 and ACP-101, and successful marketing campaigns suggest strong future growth potential. Given the company's profitability, robust pipeline, and undervaluation compared to peers, I am upgrading Acadia from "Sell" to "Buy". Read the full article on Seeking AlphaAnaliz Makalesi • Jan 08
Why Investors Shouldn't Be Surprised By ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 3.1x ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) is...Seeking Alpha • Nov 27
Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET
Summary NUPLAZID and DAYBUE are each delivering double-digit percentage net product sales growth. Company is on track to reach more than $1 billion in annualized net product sales in 2025. Next phase of growth could come from two late-stage assets known as ACP-101 for hyperphagia of PWS and ACP-204 for Alzheimer's Disease Psychosis. Company entered into a worldwide license agreement with Saniona to develop and commercialize SAN711 for the treatment of patients with Essential Tremor; Phase 2 study to be initiated in 2026. Read the full article on Seeking AlphaSeeking Alpha • Nov 11
Acadia Pharmaceuticals: Proving The Naysayers Wrong
Summary Today, we are revisiting with mid-cap biopharma Acadia Pharmaceuticals Inc., whose stock surged some 20% last week following Q3 results. The company beat both top and bottom-line expectations and also posted updated FY2024 guidance. Acadia Pharmaceuticals is becoming profitable, has a pristine balance sheet, and is seeing solid growth. An updated analysis around ACAD stock follows in the paragraphs below. Read the full article on Seeking AlphaCEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$380m |
| Mar 31 2026 | n/a | n/a | US$376m |
| Dec 31 2025 | US$8m | US$930k | US$391m |
| Sep 30 2025 | n/a | n/a | US$261m |
| Jun 30 2025 | n/a | n/a | US$222m |
| Mar 31 2025 | n/a | n/a | US$229m |
| Dec 31 2024 | US$8m | US$246k | US$226m |
Tazminat ve Piyasa: Catherine 'ın toplam tazminatı ($USD 8.26M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 6.99M ).
Tazminat ve Kazançlar: Catherine 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Catherine Owen Adams (56 yo)
2yrs
Görev süresi
US$8,256,518
Tazminat
Ms. Catherine E. Owen Adams is CEO & Director of ACADIA Pharmaceuticals Inc. from September 23, 2024. She served as Director of OptiNose US, Inc. since July 2020 until September 24, 2024. She serves as Ind...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 2yrs | US$8.26m | Veri yok | |
| Executive VP & CFO | 5yrs | US$3.12m | 0.039% $ 1.9m | |
| Executive VP | 2.7yrs | US$2.93m | 0.0044% $ 212.0k | |
| Executive VP and Head of Research & Development | 2.4yrs | US$2.89m | 0.011% $ 528.4k | |
| Executive VP & Chief Commercial Officer | 1.8yrs | US$857.02k | 0% $ 0 | |
| Senior VP | 1.1yrs | Veri yok | Veri yok | |
| Senior Vice President of Investor Relations & Corporate Communications | 3yrs | Veri yok | Veri yok | |
| Chief People Officer | less than a year | Veri yok | Veri yok | |
| Senior Vice President of Finance | no data | Veri yok | 0.0076% $ 364.4k | |
| Senior Vice President of Rare Disease Franchise | 1.3yrs | Veri yok | Veri yok | |
| Senior VP | 1.1yrs | Veri yok | Veri yok |
1.9yrs
Ortalama Görev Süresi
51yo
Ortalama Yaş
Deneyimli Yönetim: ACAD 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.9 yıl), bu da yeni bir ekibin varlığını gösteriyor.
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 2yrs | US$8.26m | Veri yok | |
| Independent Director | 18.3yrs | US$395.21k | 0.013% $ 645.9k | |
| Independent Director | 10.8yrs | US$385.05k | 0.060% $ 2.9m | |
| Member of the Scientific and Clinical Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 10.8yrs | US$399.03k | 0.025% $ 1.2m | |
| Member of the Scientific and Clinical Advisory Board | no data | Veri yok | Veri yok | |
| Member of the Scientific and Clinical Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 10.7yrs | US$393.94k | 0.0070% $ 338.1k | |
| Independent Chairman of the Board | 13.7yrs | US$415.54k | 0% $ 0 | |
| Independent Director | less than a year | Veri yok | 0.0012% $ 56.1k | |
| Independent Director | 3.9yrs | US$400.30k | 0.019% $ 915.9k | |
| Independent Director | 6yrs | US$392.67k | 0.019% $ 932.2k |
10.7yrs
Ortalama Görev Süresi
61.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ACAD 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.7 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/14 18:18 |
| Gün Sonu Hisse Fiyatı | 2026/09/11 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
ACADIA Pharmaceuticals Inc. 38 Bu analistlerden 20, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| null null | Baird |
| Jack Allen | Baird |
| Joel Beatty | Baird |